UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 459

Sortiert nach

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Leukemia, 2011-02, Vol.25 (2), p.341-347

2011

Volltextzugriff (PDF)

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

Leukemia, 2011-09, Vol.25 (9), p.1502-1509

2011

Volltextzugriff (PDF)

Bowel perforation in intestinal lymphoma: incidence and clinical features

Annals of oncology, 2013-09, Vol.24 (9), p.2439-2443

2013

Volltextzugriff (PDF)

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

Leukemia, 2011-12, Vol.25 (12), p.1877-1881

2011

Volltextzugriff (PDF)

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

Bone marrow transplantation (Basingstoke), 2010-09, Vol.45 (9), p.1396-1403

2010

Volltextzugriff (PDF)

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

Bone marrow transplantation (Basingstoke), 2013-10, Vol.48 (10), p.1302-1307

2013

Volltextzugriff (PDF)

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

Bone marrow transplantation (Basingstoke), 2011-03, Vol.46 (3), p.350-355

2011

Volltextzugriff (PDF)

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Bone marrow transplantation (Basingstoke), 2006-05, Vol.37 (9), p.865-871

2006

Volltextzugriff (PDF)

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

Leukemia, 2010-07, Vol.24 (7), p.1343-1349

2010

Volltextzugriff (PDF)

Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia

Bone marrow transplantation (Basingstoke), 2006-06, Vol.37 (11), p.1003-1008

2006

Volltextzugriff (PDF)

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma

Haematologica (Roma), 2012-02, Vol.97 (2), p.262-269

2012

Volltextzugriff (PDF)

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2008-06, Vol.41 (11), p.919-925

2008

Volltextzugriff (PDF)

G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT

Bone marrow transplantation (Basingstoke), 2013-02, Vol.48 (2), p.303-304

2013

Volltextzugriff (PDF)

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2006-06, Vol.37 (11), p.1017-1022

2006

Volltextzugriff (PDF)

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2004-02, Vol.33 (3), p.291-298

2004

Volltextzugriff (PDF)

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

Bone marrow transplantation (Basingstoke), 2008-04, Vol.41 (8), p.715-720

2008

Volltextzugriff (PDF)

CD34 cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

Bone marrow transplantation (Basingstoke), 2010-12, Vol.45 (12), p.1699-1703

2010

Volltextzugriff (PDF)

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma

Bone marrow transplantation (Basingstoke), 2003-08, Vol.32 (3), p.317-324

2003

Volltextzugriff (PDF)

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

Bone marrow transplantation (Basingstoke), 2018-02, Vol.53 (2), p.146-154

2018

Volltextzugriff (PDF)

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

Bone marrow transplantation (Basingstoke), 2011-02, Vol.46 (2), p.291-293

2011

Volltextzugriff (PDF)

Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

Bone marrow transplantation (Basingstoke), 2018-02, Vol.53 (2), p.146

2018

Volltextzugriff (PDF)

Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents

Hematological oncology, 2023-06, Vol.41 (S2), p.366-368

2023

Volltextzugriff (PDF)

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma

Bone marrow transplantation (Basingstoke), 2010-03, Vol.45 (3), p.490-497

2010

Volltextzugriff (PDF)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

Blood cancer journal (New York), 2017-08, Vol.7 (8), p.e595-e595

2017

Volltextzugriff (PDF)

IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

1 – 25 von 459

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(412)
Mit Volltextzugriff
(434)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(219)
Life Sciences & Biomedicine
(206)
Humans
(177)
Male
(134)
Female
(133)
Middle Aged
(132)
Adult
(114)
Aged
(108)
Hematology
(105)
Biological And Medical Sciences
(84)
Medical Sciences
(83)
Oncology
(83)
Aged, 80 And Over
(48)
Lymphoma
(47)
Hematologic And Hematopoietic Diseases
(46)
Retrospective Studies
(45)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(44)
Prognosis
(44)
Treatment Outcome
(44)
Transplantation
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(104)
Journal Of Clinical Oncology
(49)
Biology Of Blood And Marrow Transplantation
(26)
American Journal Of Hematology
(22)
Bone Marrow Transplantation
(21)
British Journal Of Haematology
(17)
Leukemia & Lymphoma
(12)
Therapie
(11)
Leukemia
(8)
Hematological Oncology
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

Bowel perforation in intestinal lymphoma: incidence and clinical features

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

CD34 cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Suchergebnisse filtern